• Publications
  • Influence
A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor
Purpose: To conduct a phase I clinical trial with a second-generation oncolytic herpes simplex virus (HSV) expressing granulocyte macrophage colony-stimulating factor (Onco VEXGM-CSF) to determineExpand
  • 422
  • 22
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
BACKGROUND Sunitinib, a vascular endothelial growth factor pathway inhibitor, is an effective treatment for metastatic renal-cell carcinoma. We sought to determine the efficacy and safety ofExpand
  • 377
  • 15
  • PDF
Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer
Purpose: Prostate cancer (PC) is the second most common cause of cancer related death in men. A number of key limitations with prostate specific antigen (PSA), currently the standard detection test,Expand
  • 100
  • 10
  • PDF
Measles virus causes immunogenic cell death in human melanoma
Oncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of humanExpand
  • 128
  • 9
  • PDF
The role of HOX genes in normal hematopoiesis and acute leukemia
The homeobox (HOX) genes are a highly conserved family of homeodomain-containing transcription factors that specify cell identity in early development and, subsequently, in a number of adultExpand
  • 218
  • 8
  • PDF
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.
The three-way interaction between oncolytic viruses, the tumor microenvironment, and the immune system is critical to the outcome of antitumor therapy. Classically, the immune system is thought toExpand
  • 170
  • 6
Delayed Disease Progression after Allogeneic Cell Vaccination in Hormone-Resistant Prostate Cancer and Correlation with Immunologic Variables
Purpose: There are a significant number of patients with asymptomatic hormone-resistant prostate cancer who have increasing prostate-specific antigen (PSA) levels but little or no evaluable disease.Expand
  • 126
  • 6
  • PDF
Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients
Oncolytic reovirus is carried by cells to tumors and protected from neutralizing antibodies in the circulation. Therapeutic Virus Hide-and-Seek Oncolytic viruses (OVs) selectively kill cancer cellsExpand
  • 127
  • 6
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate‐pulsed cells: a phase I/II study
To assess the feasibility, toxicity and immunogenicity of dendritic cell (DC)‐based immunotherapy in patients with advanced urological cancers.
  • 104
  • 6
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
PURPOSE Cyclophosphamide is a bifunctional alkylating agent long associated with immune activation. Continuous, uninterrupted, low (so-called metronomic) doses of cyclophosphamide can lead toExpand
  • 103
  • 6
  • PDF